• Edgewise Therapeutics published a presentation with topline 12-week Phase 2 CIRRUS-HCM Part D results for EDG-7500 in oHCM, nHCM.
• Safety focus; no clinically meaningful LVEF reductions reported, no participants recorded LVEF below 50% across oHCM, nHCM cohorts.
• Part D enrolled 53 adults; oHCM n=20, nHCM n=33; dose escalation over 12 weeks with most patients on at least 100 mg daily.
• Strategic update outlined sale of sevasemten muscular dystrophy assets to Servier for USD 1.55 billion upfront, up to USD 2.65 billion total value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.